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EPIDERMAL GROWTH FACTOR-LIKE LIGANDS REGULATE DIMER SELECTION 
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There are thirteen known endogenous EGF-like ligands. We previously 
reported that Betacellulin (BTC) increases ligand-mediated corneal wound healing 
more than Epidermal Growth Factor (EGF) [Peterson et al. (2014) IOVS 55(5):2870-
80], although the molecular reason for this is unknown.  Despite being better at 
promoting wound healing via enhanced cell migration, BTC has reduced receptor 
affinity and weaker induction of EGFR phosphorylation. These data indicate that 
BTC’s response is not due to enhanced affinity or EGFR-kinase activity.  Receptor 
phosphorylation and proximity ligation assays indicate that BTC treatment 
significantly increases ErbB3 phosphorylation and EGFR:ErbB3 heterodimers.  BTC 
traffics EGFR at a faster rate than EGF, without noticeable differences in effector 
signaling.  Thus, we demonstrate that despite both ligands binding to the EGFR, BTC 
biases the EGFR to dimerize with ErbB3 and regulates the biological response 
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INTRODUCTION AND LITERATURE REVIEW 
Epidermal growth factor receptor physiology 
 Epidermal growth factor receptor EGFR is the first receptor discovered of the 
four member ErbB family of receptors [1].  All ErbB receptors are receptor tyrosine 
kinases that share similarities including transmembrane orientation, structure, 
function and mechanism of action.  ErbB receptors can form homo- and heterodimers 
with all family members and ligand-activated dimers initiate various intracellular 
signaling cascades.  Each receptor and ligand combination differentially affects cell 
physiology, including our model, corneal epithelial homeostasis.  
Tissue Development 
 EGFR has physiological roles that affect mammalian developmental biology as 
well as tissue maintenance and regeneration [2].  The critical role EGFR plays in 
developmental biology is most evident in EGFR null mice, which have non-viable 
embryos or underdeveloped pups that die shortly after birth [3].  The surviving pups 
display EGFR knockout specific defects in skin, hair, lungs and brain [4, 5].  Defects of 
the skin associated with EGFR inhibition include dermatitis, decreased hair follicles, 
randomized direction of follicles, curly hair and shortened-curly vibrissae [6].  Lung 
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changes with EGFR knockout mice include type II pneumocyte immaturity and 
thickened septae which can lead to pulmonary toxicity and interstitial lung disease 
[6].  Defective brain tissue attributed to loss of EGFR is complex but defined by three 
critical mechanisms of tissue development; 1) decreased proliferation 2) fewer new 
neurons reaching the olfactory bulb and 3) decreased neural cell migration.   
Although defective regulation, mutations, and deletions of EGFR reveal the 
critical functions of the receptor, there are developmental cues that the role of EGFR 
changes during maturation.  Fetal tissue ubiquitously expresses EGFR, but decreased 
number and density of EGFRs occurs in the subventricular zone in the brain during 
animal maturation, consistent with a critical role of EGFR in tissue development 
shifting to a less significant role in maintenance and regeneration [7, 8].   
Tissue Maintenance and Regeneration 
 The corneal epithelium is one tissue in which the EGFR plays a critical role in 
tissue development and regeneration.  Maintaining the structure and preserving the 
integrity of the cornea is critical to sustaining quality vision.  The clear, convex-
shaped cornea has two main functions, to focus light into the eye, and to protect the 
eye from foreign agents.  Anything that compromises the health and integrity of the 
cornea will affect the function.  Blindness associated with corneal damage is a major 
ophthalmic public health problem.  Corneal opacity afflicts 1.9 million people 
worldwide according to the World Health Organization [9]. Compromised corneal 
epithelium increases the risk of permanent corneal damage, as 28% of corneal 
opacity blindness is associated with corneal damage [9]. The most common causes of 
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corneal damage are accidental injury, surgery, ulcerations or abrasions caused by 
chronic disease or side effects from EGFR inhibitor drug therapy [10].  The cornea is 
comprised of three cell layers: the epithelium, stroma and the endothelium (Fig 1).  
Two additional layers, the Bowman’s layer and the Descemet’s membrane separate 
the individual cell layers.  Fibroblast growth factor, keratinocyte growth factor, 
interleukins, hepatocyte growth factor and endothelin all promote healing in injured 
corneas [11-13].  However, only epidermal growth factor receptor (EGFR) signaling 
has been shown to be both necessary and sufficient for corneal wound healing (Fig 
1B).    
Excluding the skin, the eye is one of the most accessible organs in the body for 
in vivo studies and treatment.  Due to its external location, treatments can be as 
simple as a drop or an injection, without invasive surgery to monitor changes.  Since 
the corneal epithelium is the first structure to show trauma after exposure to diverse 
 
Figure 1. Corneal histology and wound healing 
A) Layers of the cornea.  The epithelium is the posterior layer of the cornea consisting of 
5-7 layers of cells that control the passage of proteins into the stroma.  The stroma mostly 
consists of highly organized collagen fibers with a sparse number of keratocytes that 
refract light, which is necessary for vision.  The endothelium is a single layer of cells 
responsible for maintaining stromal fluid levels.  B) H&E stained cross sections of human 





agents [14-17], it is critical to examine corneal epithelium for ocular pharmaceutical 
testing.  EGFR is in high concentration in the cornea epithelium, and tear fluid 
contains EGF at concentrations close to the ligand’s Kd for the receptor [18, 19].  
Therefore, studying EGFR mechanics after stimulation or inhibition is critical in 
producing new and better drugs for ocular therapies.  
ErbB Receptors 
Structure and Function 
The ErbB family of receptor tyrosine kinases (RTKs) have well-established 
roles in developmental biology, tissue homeostasis, and cancer biology [20, 21]. All 
four family members [ErbB1 (Epidermal Growth Factor Receptor- EGFR), ErbB2, 
ErbB3, and ErbB4] share several structural and functional features including the 
size, the transmembrane orientation of the protein, and mechanism of activation.  
Each receptor has an extracellular region, a transmembrane helix and an 
intracellular region that includes the kinase domain and c-terminal tail [22].   
 The extracellular region of the ErbB-receptors consists of four domains that 
are responsible for ligand binding.  Domains I and III are the ligand binding domains 
and II and IV are cysteine rich domains that play defining roles in ligand-dependent 
transactivation [23-25].  The four domains work in concert, fluctuating between a 
“closed” conformation and an “open” conformation that reveals a dimerization arm 
from domain II and a tethering arm in domain IV [26, 27].  Without ligand bound, the 
receptor prefers the “closed” conformation, which is anchored together by 
interactions between the dimerization and tethering arms within the molecule [28].  
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While ligand initiates most hetero- and homodimer interactions between receptors, 
preformed “inactive” dimers are present in the absence of ligand [28, 29].   
Activation of ErbB receptors begins with ligand binding that induces receptor 
dimerization, transphosphorylation of cytoplasmic tyrosines, and docking of 
downstream effectors to those phosphotyrosines.  Once ligand binds the receptor, the 
interaction between the arms is broken and the receptor toggles to a stable “open” 
conformation.  Though the ErbB-receptors are structurally similar, each receptor has 
a specific set of ligands that are known to bind and activate the receptors.  ErbB2 is 
an exception due to its open/active conformation and no known binding ligands [30].  
Once the ligand binds domains I and III, the dimerization arm is exposed and the 
receptor is then able to either form homo- or heterodimers with the other ErbB-
family members [26, 31].   ErbB-receptors bind directly to each other instead of both 
receptors binding the same ligand; this is unique from other receptor tyrosine kinases 
[26, 31]. 
ErbB-family of receptors all consist of a transmembrane domain (TM) 
comprised of a single pass -helix.  The TM in addition to the role as anchor of the 
receptor to the membrane [22], also plays a role in receptor activation and signal 
transduction by facilitating dimerization through interactions of GxxxG-like motifs at 
the C- and N-terminal ends of the TM [32].  The C-terminal motif regulates receptor 
homodimers and the N-terminal plays a critical role in heterodimerization [33].   
ErbB3 lacks the C-terminal GxxxG-like domain, which limits the ability to form 
homodimers after ErbB3-specific ligand stimulation  [34]. 
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The intracellular region of the ErbB-receptors is comprised of a 
juxtamembrane (JM) domain, a kinase domain (KD) and a tyrosine rich C-terminal 
tail.  The activated KD facilitates the trans-phosphorylation of the C-terminal 
tyrosines after ligand binding and receptor dimerization [35].  Mutation or domain 
deletion of the JM causes termination of receptor phosphorylation [36-38], 
supporting the JM role in transphosphorylation.  The ErbB-receptor KD has an N-lobe 
(head) containing a glycine rich loop and a C-lobe (tail) containing an activation loop 
and a catalytic loop [39].  The receptors arrange in an asymmetric head-to-tail 
conformation, which permits the transphosphorylation of tyrosines in the c-terminal 
tail as the C-lobe of one receptor acts as a donor to the N-lobe of the other receptor 
[37, 40, 41].  Initially, ErbB3 was thought to be kinase inactive [42, 43].  Later findings 
revealed ErbB3 has weak kinase activity [44], which could limit the kinase signaling 
potential.  The now activated c-terminal tyrosines can interact with signaling 
molecules that have SH2 or PTB domains, which include adaptors, scaffolding 
proteins, signal transducers and transcription factors [45]. 
ErbB Ligands 
Structure and Function 
The ErbB family of receptors have eleven known ligands that bind to and activate 
specific receptors (Fig. 2).  EGFR specific ligands include epidermal growth factor 
receptor (EGF), transforming growth factor-alpha (TGF-a), amphiregulin (AR), and 
epigen (EPN).  Some of the EGF-like ligands bind multiple receptors.  Heparin binding 
epidermal growth factor (HBE), and epiregulin (EPR) and betacellulin (BTC) bind and 
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activate both EGFR and ErbB4, neuregulin (NRG) 1 and 2 activate ErbB3 and ErbB4.  
NRG 3 and 4 only activate ErbB4.  All ErbB ligands contain an EGF domain that 
consists of six conserved cysteine residues that form three disulfide bonds during 
proper protein folding [46], which facilitates ligand:receptor binding.  The consensus 
motif sequence for the EGF-like ligands is CX7CX4-5CX10CXCX where X is any amino  
acid, the C is cysteine [47].  The presence and spacing of additional specific residues 
distinguishes this family from other proteins with EGF domains like Notch and Jagged 
I [48, 49].   
EGFR ligands are in a precursor form that is anchored to the plasma 
membrane.  Juxtacrine signaling occurs between neighboring cells with ligands in this 
 
 
Figure 2. ErbB family of receptors 
The ErbB family of receptors include ErbB1/EGFR, ErbB2, ErbB3 and ErbB4.  Each 
receptor includes an extracellular region, a transmembrane domain, and an intracellular 
region.  There are eleven known ligands specific to each receptor including EGF, TGFa, AR, 
EPN, HBE, BTC, EPR and NRG 1-4. 
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confirmation.  Anchored ligands contain two extracellular sites specific to certain 
ADAM proteins that facilitate cleavage of the ligand.  Once the protein is cleaved and 
in a soluble form, it then can signal by autocrine or paracrine signaling.  Soluble EGFR 
ligands range in size from 6 to 11 kDA and utilize the same binding site.  Interestingly, 
each ligand can induce varying changes in cell physiology including enhanced 
development, migration, proliferation and differentiation [2, 19, 50, 51].  The addition 
of EGF, TGF and HBE to corneal epithelial cells, which induced greater corneal 
wound healing in vivo, reflects a part of the differential roles of EGFR ligands.  
Functional redundancy among ligands is indicative in initial studies reporting TGF, 
EGF and AR knockout mice do not show any tissue abnormalities [52].  While 
treatment with various ligands can illicit various changes in specific cell physiology, 
the redundancy in functionality maintains physiology after protein loss or inhibition.  
This redundancy can be important for consistency in cell function but is also a 
hindrance for receptor specific treatments for disease, like cancer due to 
compensatory mechanisms through unencumbered proteins.  Further studies will be 
necessary to differentiate the degree of effect each ligand has on cell physiology when 
compared to the other ligands. 
Ligand:EGFR complexes 
 Signaling events initiated by ligand induced EGFR:ligand complexes give rise 
to changes in cell physiology, and can be specific to which ligand is bound to the 
complex.  While ligand binding to receptor initiates dimerization and activation, 
dimer partners and signaling outcomes can vary.  Some factors that contribute to the 
9 
 
ligand-initiated differences in cell physiology are binding characteristics (ligand and 
receptor), phosphorylation patterns of the receptor and trafficking of the receptor.   
Ligand specific binding 
 EGFR ligands bind to the receptor with different affinity.  The seven EGFR 
ligands are divided into two categories, those with strong affinity and those with 
weak affinity.  Strong affinity ligands that bind with a lower affinity than 100nM 
include EGF, BTC, HBE, and TGF.  Weak affinity EGFR ligands that bind at >100nM 
include AR, EPR, EPN [53].  Saturation binding studies performed with EGF resulted 
in a concave up Scatchard plot, indicative of two binding affinities.  There are two 
different explanations for this phenomenon: 1) the presence of two different 
populations of receptors [54] or 2) negative cooperativity is occurring [55, 56].   
 In a situation where there are two different populations of receptors, it is 
possible to calculate the affinity of each receptor population.  The Kd of EGF for the 
receptor is ~0.3 nM for high and 2nM for low receptors [18].  When two populations 
are present, activation is partially controlled by receptor density, where the higher 
density of receptors may accumulate in clathrin-coated pits or lipid rafts creating high 
affinity receptors [57].  It has been suggested that low levels of EGF can activate high 
affinity receptors and higher concentrations of ligand are needed for activation of low 
affinity populations [54].  Research has shown that the EGFRs are at an equilibrium 
mixture of all conformations, and the population exhibits binding characteristic that 
reflect the distribution of the receptor between high and low affinity forms [58].  
External and internal binding of ligand, inhibitors or kinase mutations can shift the 
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conformation equilibrium and shift the receptor from a low to high affinity receptor. 
Interestingly, each activated population of receptors induces different signaling 
cascades, with the high affinity population contributing the most biologically 
compelling signaling events [54, 59]. 
A negative cooperativity model predicts that binding of the first ligand will 
reduce the binding affinity of the second [60].  Previous and recent structural studies 
show evidence for a conformational change in the extracellular domain of EGFR upon 
ligand binding in Drosophila and in vitro. [56, 60].  Therefore, this model supports the 
hypothesis that binding of the first ligand to a receptor would shift the extracellular 
domain of a dimer and impede the binding of a second ligand.  This confirmation 
change would have a similar affinity as a liganded monomer (190-220 pM) whereas 
a dual liganded dimer has a lower affinity (2.9 nM) [55].  Supporting the negative 
cooperativity model, a study has shown that a single ligand molecule is sufficient to 
activate a dimer [61] even though ligand binding facilitates receptor dimerization 
[62]. 
EGFR Signaling Mechanisms 
Once activated by ligand, the EGFR:ErbB complex initiates a labyrinth of 
signaling events.  These events include phosphorylation of downstream proteins as 
well as ligand directed trafficking of the complex.  EGFR autophosphorylation 
patterns are overlapping but have distinct signaling pathways.  The choice of ligand 
appears to influence the fate of the receptor complex through binding differences, 
ligand size, stoichiometry changes or differential effector interactions. 
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Ligand specific phosphorylation   
 The EGFR contains different tyrosine residues that once phosphorylated, 
provide a mechanism for ligand specificity, as each site allows for docking of specific 
effector molecules.  Ligand differential phosphorylation was first shown using 
phosphopeptide mapping of ErbB4 [63] using mass spectrometry.  This study shows 
that differential signaling begins with site-specific phosphorylation of the receptor 
designated by ligand choice.  Ligand specific phosphorylation was further analyzed in 
a human epidermoid carcinoma cell line (A431) using EGF and TGF to compare 
phosphorylation sites of ligands that activate EGFR [64].   Both ligands induced 
similar patterns of receptor tyrosine phosphorylation.  However, some sites (Y992, 
S1142) varied in the intensity and duration of receptor phosphorylation.  In a 
separate study, EGF and BTC induced different levels of receptor phosphorylation at 
tyrosine sites 1068 and 1173. These differences are associated with changes in 
downstream effectors including Shc, Ras and Raf proteins [65].     
 Ligand specific trafficking 
The endocytic pathway can regulate the EGFR activity temporally and 
spatially.  Trafficking of the EGFR can be altered based on the specific ligand that 
binds the receptor.  A pivotal study comparing six EGFR ligands demonstrated that 
different ligands induced degradation, recycling or both using biochemical and 
immunofluorescent assays in HEp2 cells [66].  AR induced both rapid and slow 
recycling and EGF induced both slow recycling and degradation.  TGF and EPR cause 
rapid recycling of the EGFR back to the plasma membrane, allowing it to be activated 
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again.  BTC and HBE cause lysosomal degradation of the receptor.  One of the main 
pathways of EGFR trafficking is clathrin-dependent endocytic trafficking.  The 
mechanisms behind ligand differential trafficking are not fully understood, but one 
factor that differs between ligands is pH sensitivity.  As the receptors travel through 
the endocytic pathway, they become involved with multiple compartments that 
become increasingly more acidic (Fig 3).  Comparing a rapid recycling ligand TGF, 
and a slow recycling/degradation ligand EGF, 50% of bound TGF dissociates from 
the receptor at a pH of 6.8 compared to 5.0 for EGF [67].  The early endosome has a 
pH of ~6.8.  When a receptor:ligand complex reaches this compartment, TGF will 
dissociate and rapidly recycle, where an EGF bound ligand will stay bound to the 
complex to late endosome [68] .  The recycling of the receptor also has physiological 
effects due to the repeated availability of the receptor after returning to the plasma 
membrane, which is reflected where treatment with TGF increases corneal 
epithelial migration when compared to EGF [69].   
Degradation is another important trafficking event that regulates the receptor 
by down regulation. Degradation involves E3 ubiquitin ligase c-Casitas B-lineage 
Lymphoma (c-Cbl), which ubiquitylates the EGFR.  c-Cbl is known to dock directly to 









Figure 3.  EGFR Endocytic Pathway- The EGFR undergoes ligand-dependent, clarhrin-
mediated endocytosis with physiological concentrations of ligand.  When ligand binds 
the receptor, it dimerizes and the ligand-receptor complex translocate to a clathrin-rich 
region.  This region invaginates and forms a clathrin-coated pit that pinches off and forms 
a clathrin-coated vesicle.  Once the clathrin is shed from the vesicle, it fuses with an early 
endosome.  The early endosome then matures into a late endosome that fuses with the 
lysosome where the receptor is degraded (1).   The receptor also can be recycled back to 






























Since Stanley Cohen’s discovery of EGF in 1962 and subsequent discovery of 
EGFR in 1970s, EGFR has been well characterized and described as the prototypical 
tyrosine kinase that is critical for tissue development and maintenance.  However, 
regulation of the receptor is critical to maintaining the health and longevity of the 
tissue.  Since the initial discovery of EGF, six additional EGFR specific ligands were 
found, including BTC [71], first reported as a mitogen in pancreatic  cell tumors.   
While BTC has similarities to the other EGFR ligands, it displays some unique 
properties [72].  BTC contains two cysteines that can form a fourth disulfide bridge, 
in addition to the six-cysteine consensus of the EGF motif.  The human membrane-
bound precursor form of BTC contains an Arg-Gly-Asp (RGD) sequence, suggesting an 
active role in mediating cell-cell interactions.  In in vitro studies, BTC effects cell 
proliferation, differentiation, and survival, like other members of the EGF-like ligand 
family [72]. 
BTC is expressed in several tissues, but is found at high levels in the lung, 
kidney, and uterus [71].  Not surprisingly, high expression of BTC is also found in the 
pancreas where it seems to play a role in islet regeneration [73-75].  BTC is also found 
in milk [76], suggesting a role in the mammary gland or involvement in the 
development of the gastrointestinal tract of newborn mammals.  Accelerated growth 
of gastrointestinal organs in rats occurred following the administration of 
recombinant BTC in rats [77].  Interestingly, mice lacking BTC had no visible 
physiology changes, no overt defects and no changes in viability or fertility [78].  This 
supports the functional redundancy within the EGF ligand family. 
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Overexpression of BTC has been associated with pancreatic cancer, breast 
cancer, endometrium and endometrial cancer [79-81].  While the overexpression of 
BTC has been associated with various cancers, a BTC transgenic mouse model with 
ubiquitous overexpression of the ligand caused a plethora of phenotypic changes 
[82].  The BTC transgenic mice exhibited high early postnatal mortality, reduced body 
weight gain, and impaired longitudinal growth.  Additionally, there were cataracts 
and abnormally shaped retinal layers as well as bone alterations leading to a dome-
shaped, round head that were hallmarks of BTC transgenic mice.  Pulmonary 
pathology primarily characterized by alveolar hemorrhage, thickening of the alveolar 
septa, intraalveolar accumulation of hemosiderin-containing macrophages, and 
nodular pulmonary remodeling all proved to be the most lethal characteristic of 
overexpression of BTC. 
An in vitro study indicated BTC as the most efficacious mediator in corneal 
wound healing, including cellular migration [19], but in vivo studies revealed EGF as 
the most effective corneal wound healing ligand.  Clinical studies using EGF as a 
treatment of wound healing showed varying results in exogenous treatment with 
EGFR ligands [83-86].  This variability could be a result of endogenous ligand 
variability, the extent of the wound or the health of the eye and patient.   
Binding and Dimerization  
 The ability of EGF-like ligands to bind to various members of the ErbB receptor 
family complicates the study of ligand initiated cross-linked signaling pathways.    HB-
EGF and BTC are the only two EGFR ligands that can induce homodimers of EGFR and 
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ErbB4 [72].  Betacellulin is unique because it binds only two receptors, but can 
ubiquitously activate all the ErbB family of receptors.  While it is well accepted that 
BTC binds and activates both EGFR and ErbB4, the activation and binding of ErbB3 is 
still controversial.  Studies have shown that BTC does not bind nor activate ErbB3 [53, 
87, 88], reported weak binding and activation [72, 89], and finally, there is evidence 
of robust activation [90, 91].  In general, BTC is not considered an ErbB3 ligand due 
to the availability of other receptors for heterodimers when the receptor is activated, 
or ligand concentrations are above physiologically relevant levels.  
 No known ligand binds to the ErbB2 receptor, but it is recognized as the most 
likely heterodimer partner to all the ErbB ligands.  ErbB2:ErbB3 heterodimers have 
been labeled as the most oncogenic pairing of all the ErbB family of receptors due to 
their involvement in cell proliferation [89, 91].  Several studies show that ErbB3 
cannot be activated without ErbB2, but these studies focus on the ErbB3 specific 
ligands Neu1 and Neu2 [92, 93] or cancer biology [94].   
Although ErbB3 activation and dimerization is not well understood, the basic 
physiology of the ErbB-receptors and ligands is well analyzed.  The next step in 
understanding the ErbB-family signaling and regulation will include studies that 
directly compare each ligand to the others.  This study is important to dissecting 
which ligands initiate specific physiology changes, and eventually, which pathways 








  BETACELLULIN BIASES THE EGFR TO DIMERIZE WITH ERBB3 
 
Introduction 
The ErbB family of receptor tyrosine kinases (RTKs) have well-established 
roles in developmental biology, tissue homeostasis, and cancer biology [20, 21]. All 
four family members [ErbB1 (Epidermal Growth Factor Receptor- EGFR), ErbB2, 
ErbB3, and ErbB4] share a number of structural and functional features including 
their size, transmembrane orientation of the protein, and mechanism of activation.  
Activation of ErbB receptors begins with ligand binding that induces receptor 
dimerization, transphosphorylation of cytoplasmic tyrosines, and docking of 
downstream effectors to those phosphotyrosines. These activated effectors induce 
biochemical changes that lead to modifications in cell biology. Each ErbB family 
member is unique in its activating ligands, degree of kinase activity, and cadre of 
downstream effectors.  These features confer receptor-specific biochemical signals, 
which regulate the resulting cell biology. 
Receptor specific ligands initiate ErbB RTK signaling.  There are 13 known 
ligands for the ErbB family of proteins, each encoded by a distinct gene [95]. These 
                                                          





ligands differ in their tissue distribution as well as their rates of association and 
dissociation to each receptor. Not only do ligands drive the specificity of 
receptor:effector interactions, but also the duration and magnitude of effector 
response through differences in membrane trafficking [96, 97]. Ultimately, the ligand 
specific mechanisms influence the cellular and physiological responses.  
Despite the appreciation that ligands can induce receptor-specific signaling 
events, the molecular basis for these differences are not always clear due to the 
intrinsic barriers to ligand analysis. Knockdown of the EGFR results in embryonic 
lethality in mice, or death shortly after birth, highlighting its role in embryonic 
development [98]. In contrast, mice engineered to individually knock out epidermal 
growth factor (EGF) [52], transforming growth factor-[99], epigen [100], heparin 
binding-EGF [78], betacellulin (BTC) [78], or amphiregulin [52] reveal no lethal 
ligand-specific phenotypes and all mice were viable and fertile. More subtle 
phenotypes include minor defects, such as altered epithelial tissue homeostasis, 
mammary tissue development, or a “wavy” phenotype of the hair [101]. The distinct 
knockout phenotypes indicate ligand-specific roles in tissue development and 
homeostasis. Absence of lethality when a single ligand is knocked out is consistent 
with functional redundancy among the ligands for the EGFR’s most critical functions. 
While the overlapping roles of the ligands are likely beneficial to animals, analysis of 
the physiological contributions of individual ligands is difficult. In order to 
circumvent the limitations of in vivo analysis we, like many others, have turned to cell 
biology and biochemical assays to understand ligand-specific signaling.  
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Among the endogenous EGFR ligands, BTC is one of the most poorly 
understood. It was first identified as a secreted growth factor from pancreatic -cell 
insulinomas [71, 102], and has been implicated in a number of physiological 
processes, including -cell proliferation [74], keratinocyte proliferation [103], and 
angiogenesis [104]. In endometrial, liver, and pancreatic cancers, BTC levels are 
elevated [79, 80, 105].  BTC is a dual-specificity ligand that binds both EGFR and 
ErbB4 [106, 107]. It has been argued that BTC also binds ErbB3 [108].  The most 
compelling evidence for this comes from 32D myeloid progenitor cells that lack 
endogenous ErbB RTKs. When ErbB2 and ErbB3 are exogenously expressed, there is 
ErbB2 and ErbB3 tyrosine phosphorylation and increased 3H-thymidine 
incorporation (DNA synthesis) [91]. However, a more systematic analysis used ErbB 
RTKs expressed individually or in pairs; these studies demonstrated that measurable 
binding of BTC only occurs when EGFR and ErbB4 are expressed [53].  
BTC-null mice are viable and exhibit no overt phenotypes or problems with 
fertility; however, the life span of these mice is reduced [78]. While the lack of BTC 
demonstrates a positive role in cell biology, overexpression of BTC causes abnormal 
hair follicle development [104], increased glucose tolerance [109], and altered 
corneal development [82]. In corneal epithelial cells, BTC is more efficacious than EGF 
in mediating wound healing [19]. Despite evidence that BTC enhances wound healing 
under both physiological and pathological conditions, the molecular mechanism by 
which BTC enhances this process is unclear. These data illustrate the long-standing, 




In this study, we found that BTC is a better mediator of cell migration than EGF, 
despite a lower affinity for and reduced phosphorylation of the EGFR [110]. The 
reduced receptor phosphorylation is due to the EGFR’s formation of heterodimers 
with the kinase impaired ErbB3. Biochemical evidence for these heterodimers comes 
from the ability of BTC to promote ErbB3 phosphorylation in the absence of ErbB2. 
Cell biological evidence of EGFR:ErbB3 heterodimers is visualized with proximity 
ligation assays. When ErbB3 signaling is antagonized or depleted using an ErbB3 
antibody MM-121 [111] or siRNA, cell migration is reduced more in response to BTC 
than EGF; further indicating BTC mediates migration through ErbB3. Together, these 
data provide a new model in which a ligand can bias dimerization partners of the 
EGFR and affect cell physiology [112]. 
 
Experimental Procedures 
Cell lines – hTCEpi cells were obtained from Geron Corp. (Menlo Park, CA). Human 
corneal epithelial cells were immortalized by the stable transfection of human 
telomerase reverse transcriptase [113].  Cells were grown in growth media (Defined 
Keratinocyte with growth supplement; Invitrogen, Carlsbad, CA) at 37°C and were 
maintained at 5% CO2.  MDA-MB-468 cells were acquired from the ATCC. Cells were 
maintained in growth media [Dulbecco’s Modified Eagle Medium (DMEM)] 
supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillin, 1% streptomycin, 
and 2 mM glutamine all acquired from Life Technologies (Grand Island, NY). Cells 
were maintained at of 37 ºC in 5% CO2.  
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Materials – EGF, BTC, and NRG4 were purchased from Prospec-Tany TechnoGene Ltd 
(Rehovot, Israel). MM-121 (seribantumab) was a kindly provided by Merrimack 
Pharmaceuticals, Inc, (Cambridge, MA) [111].   All other chemicals were purchased 
from Sigma-Aldrich unless otherwise noted. 
Single cell growth assay - hTCEpi cells were plated at a density of 30 cells/well in a 12 
well tissue culture dish in low serum media (25% growth media and 75% serum free 
media). Cells were grown to the eight cell stage then treated with EGF or BTC [1.6 nM] 
or no ligand. Photographs of the cell colonies were taken every 24 hours. At each time 
point, the number of cells per colony were counted and the area the colony covered 
was measured using Image J software [114]. 
Competition binding – All radioligand binding experiments used binding buffer 
(DMEM (without bicarbonate), 10mM NaHEPES, 0.1% BSA, pH 7.4).  Confluent 12-
well dishes of hTCEpi cells were incubated with varying concentrations of cold ligand 
(EGF, BTC, NRG4) and 125I-EGF (Perkin Elmer Life Sciences, catalog no. NEX160; 
specific activity 150-200 Ci/g, ~10,000 cpm/10μl). Cells were incubated on ice for 
2 hours allowing a steady state binding while preventing membrane trafficking. Cells 
were washed 4 times with radioligand binding buffer, solubilized in 0.1% SDS/0.1N 
NaOH and radioactivity level of each sample was determined using a Beckman 
Coulter gamma counter (Brea, CA). Data are plotted as the percentage of maximal 
radioactivity as determined from cells with no competitive ligand added. IC50 values 
were calculated using a one-site model using GraphPad Prism 5.0 (La Jolla, CA).  
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pH dissociation binding – Confluent 12-well dishes of hTCEpi cells were incubated 
with 125I-EGF or 125I-BTC (~10,000 cpm/10μl). Cells were incubated on ice for 2 hours 
allowing a steady state distribution of the ligands. The pH of radioligand binding 
buffer was adjusted with NaOH or HCl to bring the buffer to the desired pH (2 – 8). 
pH-adjusted buffer was used to wash the cells to remove excess ligand and dissociate 
the ligand from the receptor. Cells were solubilized in 0.1% SDS/0.1N NaOH and the 
associated radioactivity in each sample was determined using a Beckman Coulter 
gamma counter. Data are plotted as the average (± S.E.M.) percentage of radioactivity 
relative to maximal binding.   
Western blot with phospho-specific antibodies – hTCEpi cells were washed twice with 
PBS pH 7.4 and incubated with serum-free KSFM for 2h. Cells were treated with the 
indicated ligand concentration at the indicated time. Treated cells were subjected to 
two quick washes with PBS pH 7.4, equilibrated to 4°C on ice. Cells were harvested in 
RIPA buffer (150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM 
Tris, pH 8.0, 10 mM sodium pyrophosphate, 100 mM sodium fluoride) supplemented 
with 2 mM Phenylmethylsulfonyl fluoride (PMSF), solubilized with end over end 
rotation for 10 min at 4°C. Insoluble material was removed by centrifugation for 10 
min at 4°C and maximum speed (21,130 rcf) in an Eppendorf 5424R (Hamburg, 
Germany). Equivalent amounts of cell lysate were resolved by SDS-PAGE and 
transferred to nitrocellulose. The indicated proteins were immunoblotted using the 
following antibodies: EGFR (SC-03) and EGFR (A-10) antibodies obtained from Santa 
Cruz Biotechnology (Dallas, TX), site specific phospho-EGFR antibodies (pY992, 
pY998, pY1045, pY1068, pY1148, and pY1173) were from Cell Signaling (Danvers, 
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MA), -tubulin antibodies were from Sigma-Aldrich (St. Louis, MO). Following 
incubation with the appropriate HRP-conjugated secondary antibody, 
immunoreactive proteins were visualized with ECL and a Fotodyne Imaging system 
(Hartland, WI). 
Immunoprecipitations - Cell lysates (500 g, see “Western Blot”) were incubated with 
either a pool of phospho-tyrosine antibodies (pY20, sc-508; pY99, sc-7020 from Santa 
Cruz Biotechnology, Santa Cruz, CA and 4G10, 05-321 from EMD Millipore, Billerica, 
MA) or ErbB3 antibodies (sc-285, sc-7390, sc-415, Santa Cruz Biotechnology, Santa 
Cruz, CA)(HER3/ErbB3 (D22C5) XP, Cell Signaling) while rotated end over end at 4oC 
overnight. Protein A/G agarose beads (Santa Cruz Biotechnology, Dallas, TX) washed 
with RIPA buffer were added and rotated end over end at 4oC for 2 hours. Lysates 
were centrifuged and a sample of the supernatant was kept as pass through (PT), the 
rest discarded. Then, RIPA buffer was used to wash the beads three times. To elute 
the protein from the beads, SDS sample buffer was added to the samples and heated 
to 100◦C for three minutes. The immunoprecipitates were divided into thirds, 
separated by SDS-PAGE, transferred to nitrocellulose, and detected with the indicated 
antibody EGFR and PY99 (Santa Cruz Biotechnology, Dallas, TX); ErbB2 and ErbB3 
(Cell Signaling); ErbB3 (Santa Cruz Biotechnology, Dallas, TX, Cell Signaling), as 
described previously. 
PLA Proximity Ligation Assay (PLA) - hTCEpi cells were plated on NaOH cleaned 12mm 
round #1 coverslips in a 24-well plate and grown to 70-80% confluency.  Serum-
starved cells were treated with media, EGF (16 nM), or BTC (16 nM) at 37◦C for 15 
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min.  Coverslips were washed with PBS++ (PBS pH 7.4 /0.25 M CaCl2/0.25M MgCl2) 
and fixed with 4% paraformaldehyde/PBS++ for 5 min on ice and 15min at room 
temperature.  Cells were permeabilized with 0.1% saponin/0.5% fetal bovine 
serum/PBS++ for 15 min, washed 3 times in PBS++. EGFR homodimers and 
EGFR:ErbB3 heterodimers were detected using Proximity Ligation Assay kit 
(DuoLink, Sigma Aldrich) according to manufacturer’s directions. Primary antibodies 
EGFR (E114, RabMAb Abcam) and ErbB3 (2F12, Thermo Scientific) were used 
independently and jointly as indicated in experiments. Fluorescence images and 
quantification were acquired using a Nikon Eclipse Ti-E widefield microscope using 
Nikon NIS Elements software (Nikon, Melville, NY). 
Transwell migration assay - 100,000 hTCEpi cells in serum- free media (Keratinocyte 
Defined Media without growth supplement, 100 L; Invitrogen) with or without 170 
g/ml MM-121. were plated in the upper chamber of an 8 m polycarbonate 
membrane, 6.5-mm insert (Corning, Inc., Corning, NY) for 2 hours at 37°C. Following 
incubation, the lower chamber contained 600 L serum-free media containing the 
indicated concentrations of growth factor with or without MM-121 (seribantumab, a 
gift of Merrimack Pharmaceuticals, Cambridge, MA). Cells were allowed to migrate 
for 16 hours at 37°C in 5% CO2. Migrated cells were determined by fixing the cells in 
methanol, staining in Giemsa, and counting the migrated cells under a microscope 
(TE-2000; Nikon, Tokyo, Japan) with a 60X objective[115]. 
siRNA – The siRNA were obtained from the following sources: scramble control siRNA 
(siCON), EGFR and ErbB2 were acquired from IDTDNA (Coralville, IA), ErbB3 Silencer 
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Select was acquired from ThermoFisher Scientific, Waltham, MA).  hTCEpi cells were 
transfected with the indicated siRNA by Amaxa electroporation as described 
previously [116]. Cells were allowed to recover for 48 hours. Cells were assayed by 
western blot for knockdown efficacy, phosphorylation of receptors or cell migration 
as described in materials and methods. 
Statistical analyses – Statistical tests are indicated in the figure legends and were 
performed using GraphPad Prism 5.0 (La Jolla, CA). 
 
Results 
BTC induces more cell migration than EGF 
Our previous studies identified BTC as a more efficacious mediator of in vitro 
corneal epithelial wound healing than EGF [19]. Corneal epithelial wound healing is a 
multi-faceted process that includes cell migration and proliferation [117]. The first 
goal for understanding the molecular basis for BTC’s enhanced activity was to 
determine if the ligand was augmenting cell migration, cell proliferation, or both 
processes. To assess ligand effect on proliferation and migration, hTCEpi cells were 
plated as single cells and cultured in media alone or media supplemented with EGF 
or BTC. The same colony was photographed over 72 hours (Fig 4A). From these 
images, the number of cells and their total area was determined (Fig 4B, 4C). Cells 
grown in the presence of BTC covered a larger area of the dish as compared to those 
grown in EGF or media alone indicating the BTC-treated cells were more migratory. 
Importantly, treatment with EGF increased the number of cells. 
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To supplement that assay, a Transwell assay was used to directly measure cell 
migration in response to the growth factors (Fig 4D). BTC had a 6-fold increase in cell 
migration as compared to 4-fold increase with EGF. Together, these assays 
demonstrate that BTC more efficaciously promotes cell migration as compared to 
EGF. 
Figure 4. BTC is a more efficacious activator of cell migration than EGF. A-C) hTCEpi 
cells were plated as single cells (30 cells/35 mm dish) in media alone, 1.6 nM EGF, or 1.6 
nM BTC (Peterson, JL). A) Once cell colonies formed, they were imaged at 24 hour 
intervals for 72 hours. Shown are representative data from an experiment repeated three 
times (n= 3-4 experiments, ~25-70 colonies for each condition). Scale bar = 200 m. B) 
Data from three separate experiments were plotted as average ± S.D. fold change as 
number of cells per colony.  C) Data from three separate experiments were plotted as 
average ± S.D. fold change in area per cell. D) hTCEpi cell migration was measured using 
a Transwell assay after migrating for 16 hours as described in Experimental Procedures 
(Rush, JS). Cells were incubated in serum free media with no additions (Media), serum 
(Serum), 1.6 nM EGF, or 1.6 nM BTC. Plotted are the fold changes in cell migration 
(relative to serum free media) for each condition (n=6).  Data were analyzed using a two-





BTC binds EGFR with lower affinity. 
BTC is universally accepted to bind both EGFR and ErbB4 [90, 118], but others 
report that BTC can bind/activate ErbB2 and ErbB3 as well [87, 91].  hTCEpi cells do 
not express ErbB4 [19], so we restricted our focus to the EGFR. To determine if EGF 
and BTC were binding the same receptor, we performed an 125I-EGF competition 
binding assay. EGF, BTC, and Neuregulin 4 (NRG4) as a negative control, were used to 
compete for radiolabeled EGF (Fig 5A). EGF (IC50= ~2 nM) was able to compete for 
125I-EGF binding with a 30-fold higher affinity than BTC (IC50= ~60 nM); 100 nM 
NRG4 was unable to displace 125I-EGF binding, consistent with its role as an ErbB4 
specific ligand (Fig 5A). These data indicate that EGF and BTC compete for the same 
binding site and BTC has a lower affinity for the EGFR.   
Next, we examined whether EGFR binding of BTC and EGF, had differing 
sensitivities to pH. As the ligand:receptor complex progresses through the endocytic 
pathway, it moves through an increasingly acidic environment.   Ligand binding is one 
of the factors that determines if the receptor recycles back to the plasma membrane 
or is targeted to the lysosome.  Approximately 50% of bound 125I-EGF dissociated at 
pH 5.8, whereas a pH of 4.3 was required to dissociate 50% of the bound 125I-BTC (Fig 
5B). These values led to the prediction that ~50% of EGF:EGFR complexes will 
dissociate in the early endosome [pH ~5.9-6.8 [119]], whereas, the BTC:EGFR is not 




BTC induces less EGFR phosphorylation but more ErbB3 phosphorylation 
Consistent with the reduced affinity, BTC was a weaker activator of EGFR, as 
compared to EGF. Using ligand concentrations that produced maximal cell migration 
[19], a time course of tyrosine phosphorylation was used as a read-out of EGFR 
activity (Fig 6). hTCEpi cells treated with BTC as compared to those treated with EGF 
had reduced EGFR phosphorylation at all four of the tyrosine residues examined (Fig 
 
Figure 5. BTC and EGF bind EGFRs with different affinities and pH sensitivities. A) 
125I-EGF competition binding using varying concentrations of EGF, BTC, or NRG4 as 
indicated. B) pH sensitivity of 125I-EGF and 125I-BTC binding. Cells were incubated with 
radioligand at pH 7.4 and 4C until steady-state binding was achieved. Cells were then 
incubated in binding buffer at varying pH at 4C for 30 minutes, then washed three times 
in ice cold buffer of the same pH. Cells were solubilized and associated radioactivity was 
measured. For (A-B), data are plotted as the percent of maximal radioligand binding 
(average ± S.D., n=3) (Peters JL).   
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6A). Similar trends were observed in MDA-MB-468 cells, a metastatic breast cancer 
cell-line with comparable levels of EGFR (Fig 7). 
 
 
Figure 6. BTC is a less efficacious activator of EGFR phosphorylation in hTCEpi 
cells. Cells were treated with 1.6 nM EGF or 1.6 nM BTC for the indicated times. Cell 
lysates were prepared and immunobloted with the indicated EGFR phosphotyrosine 
specific antibodies (pY998, pY1045, pY1068, pY1148), total EGFR, or -tubulin. A) 
hTCEpi cell representative blots from three experiments (Peterson JL).  B-F) Western 
blots quantified using ImageJ software.  Phosphotyrosine blots were normalized to the 
30 min timepoint, total EGFR is normalized to untreated EGFR levels (Rush JS). 
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The decrease in EGFR phosphorylation led us to an alternative explanation. We 
hypothesized that EGF promoted EGFR homodimers, whereas BTC preferentially 
formed EGFR:ErbB3 heterodimers. The model accounts for the observation that 1) 
the ligands can compete for binding with one another [53, 120], 2) the EGFR:ErbB3 
heterodimers would have reduced EGFR phosphorylation due to ErbB3 being kinase 
impaired [42], and 3) ErbB3 activation is associated with induced proliferation and 
migration [121-123].  
To test whether BTC could differentially signal through other ErbB receptors, 
we examined receptor phosphorylation (Fig 8). hTCEpi cells were treated with media 
alone, or media supplemented with EGF or BTC.  Denatured cell lysates were 
immunoprecipitated with an anti-phosphotyrosine antibody and probed for the 
presence of the three endogenous ErbB receptors (Fig 8A).  BTC treatment led to 
 
Figure 7. BTC is a less efficacious activator of EGFR phosphorylation in MDA-MB-
468 cells. Cells were treated with 1.6 nM EGF or 1.6 nM BTC for the indicated times. Cell 
lysates were prepared and immunobloted with the indicated EGFR phosphotyrosine 
specific antibodies (pY998, pY1045, pY1068, pY1148), total EGFR, or -tubulin. A) MDA-
MB-468 cell representative blots from three experiments. B-E) Western blots from A) 
were quantified using NIH ImageJ software.  Data are presented as a ratio of each 
treatment to the most abundant protein. 
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decreased phosphorylation of EGFR and ErbB2 when compared to EGF, whereas only 
BTC treatment resulted in significant ErbB3 phosphorylation (Fig 8D). Significant 
ErbB3 phosphorylation by BTC was also observed when cell lysates were 
immunoprecipitated using an ErbB3 antibody and immunoblotted with an anti-
phosphotyrosine antibody (Fig 8B, 8E).  
hTCEpi cells were transduced using ErbB2-specific shRNA to examine the 
possibility of ErbB2 involvement in ErbB3 phosphorylation.  BTC-mediated 
activation of ErbB3 is unaffected by the loss of ErbB2 (calculated to be 86% 
knockdown), further indicating that ErbB2 is dispensable in BTC activation of ErbB3 
(Fig 8C, 8F).  To determine whether these observations were specific to hTCEpi cells, 
we treated MDA-MB-468 cells with EGF and BTC, and then immunoprecipitated 
phosphorylated tyrosines and immunoblotted for the same three ErbB receptors 
available in hTCEpi cells (Fig 9A-D). MDA-MB-468 cells express EGFR and ErbB3, but 
do not express detectable levels of ErbB2 or ErbB4 [124](Figure 9A-D). As with the 
hTCEpi cells, BTC treatment resulted in less EGFR tyrosine phosphorylation, and 













Figure 8.  BTC induces ErbB3 phosphorylation in hTCEpi cells without ErbB2 
interaction.  A-C) hTCEpi were treated with serum free media alone, 1.6 nM EGF, or 
1.6 nM BTC for 15 min as indicated. Cell lysates were prepared under denaturing 
conditions and the indicated proteins were immunoprecipitated using A) anti-
phosphotyrosine (Peterson JL), or B) anti-ErbB3 antibodies. The pass-through (PT) and 
immunoprecipitates were resolved by 7.5% SDS-PAGE, and immunoblotted with the 
indicated antibodies.  Shown are representative blots from an experiment performed 
at least three times.  C) Transduced ErbB2-shRNA and shRNA control (materials and 
methods) hTCEpi cells were treated the same as A-B.  Shown are representative blots 
from three replicates. D-F) Immunoblots from A-C were quantified using NIH Image J.  
Data are presented as the average ratio (+ S.D.) of each treatment to the most abundant 
protein. Blots were analyzed with a two-way ANOVA, Holm-Sidak’s multiple 





BTC promotes ErbB3 phosphorylation and EGFR:ErbB heterodimers 
These biochemical data provide evidence that BTC causes ErbB3 
phosphorylation, but do not demonstrate a direct interaction. Another possibility is 
ErbB3 phosphorylation is mediated by a non-receptor kinase that is activated by the 
liganded EGFR.  To determine if BTC caused an increase in EGFR:ErbB3 heterodimers, 
we performed proximity ligation assays (PLA) (Fig 10).  PLA is an antibody based 
detection/amplification system that will reveal protein:protein interactions when 
 
 
Figure 9.  BTC induces ErbB3 phosphorylation in MDA-MB-468.  A-B) MDA-MB-468 
were treated with serum free media alone, 1.6 nM EGF, or 1.6 nM BTC for 15 min. Cell 
lysates were prepared and proteins immunoprecipitated using A) anti-phosphotyrosine 
or B) anti-ErbB3 antibodies. The pass-through (PT) and immunoprecipitates were 
resolved by 7.5% SDS-PAGE, and immunoblotted with the indicated antibodies.  Shown 
are representative blots from an experiment performed at least three times. C-D) Blots 
were analyzed with a two-way ANOVA, Holm-Sidak’s multiple comparisons test. 
Normalized experiments are presented as ratios compared to the strongest band for each 
blot, * = p < 0.05, ** = p < 0.01, *** = p < 0.001  NS= not significant (Rush JS). 
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they are within 40 nm. hTCEpi cells were treated with media alone, or media 
supplemented with EGF or BTC, fixed and subjected to the PLA protocol (see 
Experimental Procedures). When cells were screened for the presence of EGFR:ErbB3 
heterodimers, EGF produced a 1.1 fold increase in heterodimers, and BTC produced 
a 2.6-fold increase (Fig 10B).  Together, the receptor phosphorylation data and the 
PLA support the notion that EGF treated cells have less EGFR:ErbB3 heterodimer 
interactions when compared to those treated with BTC.  
Finally, we wanted to determine if the EGFR:ErbB3 heterodimers were 
responsible for the increase in cell mobility that was seen with BTC treatment. We 
monitored ligand-dependent cell migration using a Transwell migration assay in the 
absence and presence of the ErbB3 antagonist antibody, MM-121 (seribantumab) 
[111] (Fig 11A).  MM-121 treated cells migrate similarly with media alone, serum or 
EGF. In contrast, in the presence of MM-121, BTC treated cells no longer migrated 
more than EGF treated cells.  
To determine the contribution of ErbB family members on BTC-mediated 
migration, we knocked down EGFR, ErbB2, and ErbB3 (Fig. 11B) individually.  
Transfection of hTCEpi cells with these siRNA attenuated expression of EGFR, ErbB2 
and ErbB3 by 49%, 78% and 91% respectively.  The decreased levels of ErbB3 
eliminated the significant BTC mediated migration advantage when compared to EGF 
(Fig. 11C).  The loss of any of the three ErbB RTKs decreases the efficacy advantage of 
BTC treatments over EGF (Fig. 11C). These data are consistent with all ErbB family 





Figure 10. BTC induces EGFR:ErbB3 heterodimers in hTCEpi cells.  EGFR:EGFR or 
EGFR:ErbB3 dimerization was visualized by proximity ligation assay (PLA).  After serum 
starving cells for 2 hrs, hTCEpi cells were treated with serum free media alone or with 
16nM EGF or BTC for 15min at 37◦C.  After treatment, cells were fixed and probed using 
the proximity ligation assay (PLA) as described in Material and Methods. Representative 
micrographs of cells probed for A) EGFR:ErbB3 heterodimers. Data from three 
independent experiments were quantified (50-100 cells/experiment) and are presented 
as the total number of signals per cell (B) and analyzed with a one-way ANOVA, Holm-
Sidak’s multiple comparisons test. Normalized experiments are presented as the number 
of signals compared to untreated (C), and quantification were analyzed with an unpaired 







Figure 11. ErbB3 antagonist MM-121 and knockdown inhibit BTC-mediated 
migration to a greater extent than EGF-mediated migration.  A) hTCEpi cells were 
plated on the upper chamber of transwells (0.8 nm pore) and pre-treated without or 
with 170 g/ml MM-121 for 2 hours. The media was replaced with 1) serum free media 
alone, 2) EGF (1.6 nM) or 3) BTC (1.6 nM) in the absence or presence of MM-121. Cells 
were incubated for 16 hours and migration to the lower chamber was measured by 
counting the number of migrated cells on the underside of the membrane. Shown are 
the results of 6 independent experiments for each condition. B) hTCEpi cells were 
transfected with either control siRNA (siCON) or siRNA specific for EGFR, ErbB2 or ErB3 
as described in Materials and Methods. After recovery (72h), B) immunoblots from cell 
lysates were prepared from hTCEpi samples, and equal amounts of total protein loaded.  
Samples were resolved by SDS-PAGE and immunoblotted with the indicated antibody.  
Immunoblots shown are representative from experiments performed at least 6 times.  
C) transwells were loaded with transfected cells as described in Materials and Methods.  
Migrated cells were quantified and each experiment normalized to media treated cells 
independently.  Each y-axis indicates a different transfected hTCEpi cell-line.  The results 
are plotted as mean + S.D. Data were analyzed with a two-way ANOVA with Holm-Sidak’s 




In this manuscript, we demonstrate that EGFR-related growth factors differ in 
their ability to induce phosphorylation, direct specific receptor dimerization and 
effect cell physiology.  Multiple labs have reported that BTC is more efficacious than 
EGF [19, 90, 111, 125]. We show that in line with ligand efficacy, BTC enhances cell 
migration more than EGF (Fig 4 and 11), which is a fundamental component of 
corneal wound healing (Fig 4 and 11). Furthermore, this effect is not due to enhanced 
BTC binding to or phosphorylation of the EGFR (Fig 5 - 7), as these responses are 
reduced with BTC treatment.  Rather, BTC binding to the EGFR biases the receptor to 
heterodimerize with ErbB3, resulting in ErbB3 phosphorylation (Fig 5-10). 
Importantly, BTC-mediated ErbB3 phosphorylation is independent of ErbB2. These 
heterodimers are more efficacious mediators of cell migration, as ErbB3 antagonists 
and knockdown inhibits BTC-mediated migration to a greater extent than EGF-
mediated migration (Fig 10).  
We propose a model in which EGF and BTC both bind the EGFR, but 
differentially bias the dimerization partner of the ligand-bound receptor. This ligand-
biased signaling is known among G-protein coupled receptors [126-128]. In the cell, 
monomeric ErbB RTKs and their ligands are in a biochemical equilibrium.  The 
binding of ligand shifts the equilibrium of the receptors from a monomeric to a 
dimeric form. Our data here support a model in which the ligand:EGFR directs 
whether the dimers are homodimers or heterodimers. There is an additional layer of 
complexity to this model when applying it to other cell lines that express the ErbB 
RTKs at different levels.  
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Reports in the literature have been inconsistent regarding how BTC induces 
ErbB3 phosphorylation [118, 129-132]. We postulate that the variability in the 
absolute and relative amounts of EGFR and ErbB3 are a potential source for these 
discrepancies. Since BTC drives the formation of EGFR:ErbB3 heterodimers, if EGFRs 
are in vast excess, once the maximum number of heterodimers are formed, the 
remaining liganded EGFRs are able to form homodimers or ErbB2 heterodimers.  Our 
data support this hypothesis, as the loss of EGFR and ErbB2 also decreased the 
significant advantage BTC treatment had on migration (Fig 11).  hTCEpi cells have 
sufficient levels of EGFR and ErbB3 that produce functional EGFR:ErbB3 
heterodimers, as evident by the decreased cell migration in response to ErbB3 
antagonist and ErbB3 knockdown.  Cells that do not express ErbB3 may not show 
differences in responses to EGF and BTC migration. 
Several previous studies support this model. First, Liu et al. report that a single 
ligand is sufficient to activate EGFR dimers [61]. While this is well accepted for ErbB 
RTKs that heterodimerize with the ligandless ErbB2, it is important to note that it can 
extend to the other family members that undergo conformational changes to 
dimerize. Second, our findings that receptors preferentially form dimer partners is 
supported by the work of MacDonald-Oberman et al. [120, 133]. Our endogenous 
receptor model proposes that these preferences can be shifted by the activating 
ligand. As indicated from our PLA experiments, BTC preferentially drives the 
formation of EGFR:ErbB3.  
It was fortunate that hTCEpi and MDA-MB-468 cells do not express ErbB4, 
another target for BTC binding. With the addition of ErbB4, the model would have to 
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take into consideration the binding affinities for EGFR versus ErbB4. Although ErbB2 
does not bind BTC, its contribution cannot be overlooked.  It is likely that ErbB2 is 
also competing for binding to the liganded EGFRs. ErbB3 phosphorylation was 
unaffected by the loss of ErbB2, further supporting EGFR as the sole ligand binding 
receptor in our system.  The incomplete inhibition of ErbB3 initiated migration in 
response to MM-121 may be due to compensatory ErbB2 effects.  The knockdown of 
each ErbB RTK had an increase in protein levels of the other ErbB RTKs when 
compared to control lysates (data not shown), especially with EGFR knockdown (Fig. 
11C).  Other groups show that compensatory protein effects following knockdown of 
similar proteins are possible and support this phenomenon [134-136]. This effect 
was also supported in the receptor knockout cell lines where the loss of EGFR, ErbB2 
and ErbB3 decreased the migration advantage BTC has over EGF.  While ErbB2 is not 
necessary to activate ErbB3 with BTC, it contributes to BTC-mediated migration, like 
ErbB3 (Fig 11B).  More rigorous mathematical modeling and experimentation are 
required to account for the complexities of the entire ErbB RTK family.  
While it has been previously appreciated that ligands can direct dimer 
formation, it was largely attributed to differences between which receptor and the 
ligand bound [120]; our model proposes that two different ligands are binding the 
same receptor, but forming different heterodimer populations. How would ligand 
binding direct the dimerization partner? One possibility is that human EGF and BTC 
have limited sequence similarity (~36%) as well as low predicted three-dimensional 
structural homology as measured by solvent accessibility surfaces [108]. 
Alternatively, the size of the ligand may affect receptor conformation. The processed 
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form of BTC is 9 kDa and EGF is 6.6 kDa [46]. A stretch of ~50 amino acids directly 
binds to the ligand-binding domain of the receptor [137]. The size and/or charge of 
the remaining 30 amino acids may sterically hinder BTC:EGFR homodimerization. 
Fundamental differences in binding are supported by our observed differences in 








BTC INDUCES DIFFERENTIAL EGFR TRAFFICKING AND COMPARABLY ACTIVATES 
AKT AND MAPK 
Introduction: 
 Many tissues throughout the body express EGFR.  Once ligand binds the 
receptor, the receptor becomes activated intracellularly and is then able to activate 
effectors (i.e. Shc, Grb2, c-Cbl, MAPK, AKT).  The activities of these EGFR activated 
effectors modulate receptor trafficking and ultimately, cell physiology.  EGFR 
activation is known to alter cell survival, proliferation, differentiation and migration.  
These cellular changes then translate to functional changes in tissue development, 
wound healing, tissue maintenance and cancer biology [138, 139]. 
 The clathrin-mediated endocytic pathway is the primary molecular 
mechanism that balances EGFR signaling and regulation [140].  Ligand bound ErbB-
receptors internalize via clathrin-coated pits and initiate the activation of 
downstream signaling pathways.  The cargo, now inside the cell, travels through the 
endocytic pathway by moving from clathrin-coated vesicles to early endosomes, 
which mature to late endosomes/multivesicular bodies and finally to the lysosome 
for degradation.  This process typically attenuates the EGFR signaling adequately, 
although the complete mechanisms remain unclear due to the complexity of this 
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process.  Some possible EGFR regulatory mechanisms include dephosphorylating the 
receptor, sequestering the receptor (decreasing effector interaction), ubiquitylation, 
and relocation of the receptor from the plasma membrane [141]. 
 This study examines changes in receptor trafficking and downstream effectors 
in response to EGFR ligands EGF and BTC.  Although we found BTC significantly 
increases 1) ErbB3 phosphorylation, 2) EGFR:ErbB3 interactions, 3) migration rates 
4) EGFR trafficking rates in corneal cells, there was no measurable change in 
downstream effector signaling relative to the differences when compared to EGF.  We 
did identify that downstream signaling between EGF and BTC was similar, despite 
having decreased phosphorylation of the binding receptor, EGFR.  This finding 
indicates that other effectors/pathways are involved in EGF/BTC associated 
physiology changes, not trafficking. 
Experimental Procedures 
 
Cell Lines- hTCEpi cells were obtained from Geron Corp. (Menlo Park, CA). Human 
corneal epithelial cells were immortalized by the stable transfection of human 
telomerase reverse transcriptase [113].  Cells were grown in growth media (Defined 
Keratinocyte with growth supplement; Invitrogen, Carlsbad, CA) at 37°C and were 
maintained at 5% CO2.  HeLa cells were a gift of Sandra Schmid (The Scripps Research 
Institute) and were maintained in Dulbecco’s Minimal Essential Media (DMEM) 
containing 5% fetal bovine serum (FBS), 100 units/mL penicillin, 100mg/mL 
streptomysin, and 2 mM glutamine.   Cell lines were maintained at 37◦C in 5% CO2. 
Percoll Gradient Fractionation—Analysis of radioligand distribution was performed 
as described by Kornilova et al. (10).  Briefly, hTCEpi cells were incubated for 15 min 
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with 125I-EGF or BTC (1ng/ml) at 37 °C in binding buffer (DMEM, 20 mM HEPES, 0.1% 
bovine serum albumin (pH 7.4)). Following treatment, cells were washed three times 
with PBS and returned to 37 °C in growth media.  After another 30,45,105 min 
(45,60,120 min total), cells were washed twice with TES [10 mM triethanolamine, 1 
mM EDTA, 0.25M sucrose (pH 7.2)] and harvested in 2 ml of TES. Lysates were 
pipetted up and down 40 times and centrifuged for 10 min at 200 x g in a Sorvoll 
JA25.5 rotor. The supernatant was transferred to a clean tube and the pellet was 
resuspended in 2 ml of TES and centrifuged again. The resulting 4 ml of postnuclear 
supernatant was diluted with a 90% Percoll solution in TES to 17% in 11.5 ml. 
Samples were centrifuged for 25 min at 4 °C at 50,000 g in a Beckman Ti65 rotor to 
separate early and late endocytic compartments. Samples were fractionated into 10-
drop fractions (30 fractions/gradient) from the bottom and measured for 
radioactivity in a Beckman counter. Data are plotted as the percentage of total 
radioactivity in each tube versus the relative migration of each fraction in the sample. 
Density was monitored using density marker beads (Amersham Biosciences). 
Western Blotting - hTCEpi cells were washed twice with PBS pH 7.4 and incubated 
with serum-free KSFM for 2h. Cells were treated with 1.6 nM EGF or BTC for 15, 30, 
60, 120, 240 min. Treated cells were subjected to two quick washes with PBS pH 7.4, 
equilibrated to 4°C on ice. Cells were harvested in RIPA buffer (150 mM NaCl, 1% 
Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0, 10 mM sodium 
pyrophosphate, 100 mM sodium fluoride) supplemented with 2 mM 
Phenylmethylsulfonyl fluoride (PMSF), solubilized with end over end rotation for 10 
min at 4°C. Insoluble material was removed by centrifugation for 10 min at 4°C and 
44 
 
maximum speed (15,000 g) in an Eppendorf 5424R (Hamburg, Germany). Equivalent 
amounts of cell lysate were resolved by SDS-PAGE and transferred to nitrocellulose. 
The indicated proteins were immunoblotted using the following antibodies: EGFR 
(SC-373746) antibodies obtained from Santa Cruz Biotechnology (Dallas, TX), site 
specific phosphoEGFR antibody (pY1045), total AKT (9272, phospho-AKT, Ser473 
(4051), MAPK 42/44 (4695), phospho-MAPK 42/44 (9101) from Cell Signaling 
(Danvers, MA), -tubulin antibodies were from Sigma-Aldrich (St. Louis, MO). 
Following incubation with the appropriate HRP-conjugated secondary antibody, 
immunoreactive proteins were visualized with ECL and a Fotodyne Imaging system 
(Hartland, WI).  
Results 
EGFR Trafficking Accelerated with BTC Treatment 
  To determine whether physiological effects of ligand treatment in hTCEpi cells 
is related to changes in EGFR trafficking, we quantitatively examined 125I-EGF:EGFR 
and 125I-BTC:EGFR endosomal distribution.  Cells were treated with 125I-Ligand and 
chased with radioligand-free media (materials and methods).  Early and late 
endosomes were resolved using sedimentation velocity centrifugation from cell 
lysate using 17% Percoll gradients.  Density beads were used to verify the identity of 
the fractions.  Low density fractions (Rf ~0.3, 1.040 g/mL) correspond to early 
endosomes and higher-density fractions (Rf ~0.9, =1.080-1.109 g/mL) correspond 
to late endosomes [142]. 
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 The distribution of radioactivity in cells treated with either 125I-EGF or 125I-
BTC revealed similar trafficking and distribution of both ligands.  In HeLa cells less 
than 50% of the starting amount of 125I-EGF radioactivity remained at 120 minutes, 
with minor peaks at densities corresponding to early and late endosomes (Fig. 12A).  
Repeating the experiment using hTCEpi cells, less than 78% of the radioactivity after 
15 min. of treatment remains at 120 min. (Fig. 12B).  Then, hTCEpi cells were treated 
with 125I-BTC for 120 min. with only 28-32% radioactivity remaining (Fig. 12C).  
 Our biochemical data indicate that EGF and BTC trafficking is similar, in that 
there is no apparent accumulation in the various compartments.  However, BTC 




 EGF and BTC Initiated AKT and MAPK Signaling Pathways are Indistinctive 
 The endocytic pathway is well regulated, and activation and downregulation 
of receptors is balanced to control signaling pathways and maintain normal cell 
 
 
Figure 12. 125I-EGF and BTC Traffic Differentially- The endocytic trafficking of the 
125I-EGF:EGFR  in Hela (A) and hTCEpi (B) and 125I-BTC:EGFR complex in hTCEpi cells 
(C) was assessed by pulse-labeling cells with 125I-Ligand.  Following a 7 min. ligand 
treatment followed by radioligand-free media, post-nuclear supernatant was prepared 
at 15, 45 or 60, and 120 min. Data were plotted as the relative distribution of 125I in each 
fraction and were normalized to the total radioactivity. Circles along the x-axis indicate 
the distribution of density beads (from lowest to highest Rf ~0.30=1.040 g/mL, 
0.85=1.055 g/mL, 0.88=1.069 g/mL, 0.89=1.080 and 0.92=1.109 g/mL).  Early 
endosomes migrate at 1.035-1.042 g/mL.  The heavier late endosomes sediment with a 
density of 1.048-1.060 g/mL. 
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biology.  Ligand activation of EGFR initiates signaling cascades involving multiple 
proteins and pathways.  The physiological consequences of the activation of the 
various pathways are dependent on how, when and where proteins are activated or 
deactivated (downregulated), and potentially, which ligand initially binds to the 
receptor.  To test that the physiological changes associated with BTC activation are 
due to differences in the two main proliferation/migration signaling pathways, ligand 
time course with both ligands was used to assess phosphorylation levels of AKT 
(Ser473) and MAPK. 
 Serum starved hTCEpi cells were treated with or without 1.6 nM EGF or BTC 
for 0-240 min., and total and phosphorylated EGFR, AKT (Ser473) and MAPK (42,44) 
was measured by immunoblot analysis (Fig. 13A-C).  Densitometric analysis using 
ImageJ to quantify the difference in total phosphorylation relative to total protein 
(Fig. 13B, C).  We observed unexpected indistinguishable activation of 
proliferation/migration signaling pathways.  BTC induces comparable levels of 
activation of both AKT and MAPK compared to EGF, even though BTC induces less 




 We have demonstrated previously that BTC induces migration more efficiently 
than EGF in immortalized human corneal epithelial cells [19].  In a previous study 
(Chapter II), we demonstrated that BTC induces increased signaling of ErbB3 and 
heterodimers of EGFR and ErbB3.  From the data, we developed the hypothesis that 
increased effector signaling from ErbB3 or changes in trafficking would precede BTC 
induced enhanced migration.   
To test this hypothesis, we used hTCEpi cells and monitored EGFR endocytic 
trafficking 125I-EGF and BTC.   If the rate of EGFR trafficking increases, we would 
expect a decrease in total 125I over time; if trafficking slows, overall radioactivity 
levels would increase, as well as the amount of 125I at the density regions associated 
Figure 13.  EGF and BTC have comparable effector signaling- Cells were treated with 
1.6 nM EGF or 1.6 nM BTC for the indicated times. Cell lysates were prepared and 
immunobloted with the indicated EGFR phosphotyrosine 1045, total EGFR, phospho-
AKT(Ser473), total AKT, phospho-MAPK (42/44), total MAPK (42/44) or -tubulin. A) 
hTCEpi cell representative blots from three xperiments.  B) Western blots quantified using 
ImageJ software.  Phospho-blots were normalized to the corresponding total. 
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with early or late endosomes.  We observed similar trafficking between HeLa and 
hTCEpi cells treated with 125I-EGF, with some experimental variability. However, 
hTCEpi cells treated with 125I-BTC showed <3 fold difference in total radioactivity 
after remaining at 120 min, when compared to EGF.  Visually comparing Hela (Fig. 
12A) and hTCEpi cells (Fig. 12C) at 60 min., you can see a well-defined peak in hTCEpi 
cells in the region associated with early endosome densities.  However, the Hela cells 
at this same time point show small peaks in early and late endosomal regions and an 
overall accumulation of 125I-EGF compared with 125I-BTC.  This indicates that BTC is 
processing through the late endosome at a faster rate.  We showed previously that 
EGF dissociates from EGFR at a higher pH than BTC, allowing BTC to stay bound 
longer to EGFR throughout the endocytic pathway.  These data support a model 
where BTC can stay bound longer to the receptor, but does not apparently change the 
kinetics of ligand:receptor trafficking based on Percoll gradients.  Instead, when the 
trafficking data and receptor degradation data are combined, the complex seems to 
be trafficking through the endocytic pathway at a slightly faster rate, as supported by 
other publications [66, 143].   
 MAPK and AKT are well known pathways associated with regulating 
the migration and proliferation of cells [144-146].  ErbB3 has seven known direct 
binding sites for PI3-kinase, an upstream activator of the AKT pathway.  We 
hypothesized that BTC induced phosphorylation of ErbB3 would cause an increase of 
AKT activity when compared to EGF treatment.  We used immunoblotting to examine 
phosphorylation patterns and unexpectedly, we saw comparable, at times 
indistinguishable signaling patterns from both ligands.  This data suggests that even 
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though BTC has decreased activation of EGFR, downstream signaling is comparable, 
from heterodimer-initiated pathways.    
EGFR overexpression, hyperactivation and mutations in several types of 
cancers is associated with poor patient prognosis [147].  This connection to disease 
is harmonious with the receptor’s ability to induce cell proliferation, migration, 
differentiation and viability.  Hyperactivation of EGFR related to disease makes EGFR 
a logical pharmacological target for cancer therapies including humanized 
monoclonal antibodies (mAb) and small molecule kinase inhibitors.  mABs block the 
activation of the receptor by ligand binding, while TKIs bind the kinase domain and 
prevent receptor signaling.  While both types of EGFR inhibitors prove to be effective 
at suppressing tumor growth in the short term, most patients acquire resistance.  In 
addition, patients using EGFR inhibitor therapy experience colitis, diarrhea, 
dermatitis, and persistent corneal erosions.  A deeper knowledge of EGFR:ErbB 
trafficking, effector activation is needed to make drugs that are more effective with 
less side effects and resistance.  It has been suggested that compensatory networks 
(heterodimers, increased protein expression, etc.) could be one reason resistance 
occurs at such a high rate.   
A deeper understanding and broader knowledge of EGFR trafficking and 
signaling is needed to expand and improve targeted therapies.  This study provides 
evidence that two EGFR ligands that bind the same receptor can traffic differentially 




   
  
CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 The EGFR and the ErbB-family of receptors form a complex signaling network 
with twenty-four possible ErbB-receptor combinations directed by eleven different 
ligands.  Since the initial discovery of EGF ligand in the 60s by the Cohen group, 
researchers have elucidated some of the basic mechanics of receptor and ligand 
binding possibilities, but how ligand choice and dimer pairing effects signaling 
networks and cell physiology remains unclear.  Examining the migration rate changes 
of two ligands (EGF and BTC) bound to one ErbB-receptor (EGFR) preempted this 
study of ligand-initiated mechanisms.  Using hTCEpi cells, void of ErbB4, and limiting 
our study to two ligands that only bind EGFR, we were able to deduce a few basic 
mechanisms that are involved in BTC enhanced migration.   
 We discovered that even though BTC has decreased activation of EGFR at 
equal concentrations to EGF, it is able to activate more EGFR:ErbB3 heterodimers and 
consequentially phosphorylate more ErbB3.  The phosphorylation of ErbB3 by BTC 
could be the reason both EGF and BTC comparably activate the MAPK/AKT pathways, 
even without comparable phosphorylation of EGFR.  Both EGFR and ErbB3 have 
receptor specific binding to effectors important for cell proliferation and migration.  
ErbB3 has seven known direct binding sites for phosphatidylinositol-3-kinase (PI3K), 
where EGFR has no direct PI3K sites, but can activate PI3K through two Grb2 binding 
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sites.  Even though Grb2 can also activate PI3K, ErbB3 has more binding potential 
with PI3K, a known activator of mTOR and AKT pathways.  Both mTOR and AKT are 
important components of the proliferation and migration mechanisms in cell biology.  
 ErbB2:ErbB3 dimer pairings have been associated with proliferation and 
migration, some studies showing one without the other inhibits migration.  In our 
study, we saw that ErbB3 is activated by BTC, even without the availability of ErbB2.  
However, the loss of any of the ErbB-family of receptors in the hTCEpi cells limited 
the enhanced migration advantage BTC has compared to EGF.  This indicates that 
while BTC has the potential to activate unique signaling pathways associated with 
ErbB3 phosphorylation, without the ability to bind EGFR or ErbB2, physiological 
advantages are limited or void. 
 Because EGFR is spatially and temporally regulated, cell physiology changes 
are partially the result of how, where and how quickly EGFR traffics.  When we 
compared 125I-EGF and 125I-BTC, we found that the receptor did not appear to 
accumulate in distinct endocytic compartments.  However, when total radioactivity 
changes between 15 min. and 120 min., BTC progressed through the endocytic 
pathway at a noticeably faster rate.  We also saw that BTC remained bound to EGFR 
at a lower pH level than EGF, allowing the receptor to continue to signal throughout 
the endocytic pathway.  When the receptor complex remains activated throughout 
endocytosis, the opportunity to interact with more downstream effectors increases, 
ultimately effecting cell physiology like migration and proliferation. 
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 While this study only reveals a small part of the mechanisms involved in 
ligand-initiated cell migration and wound healing by EGFR and two of its ligands, it is 
an important step in simplifying the complex story of receptor regulation by ligand 
specification. 
Limitations of This Work 
 hTCEpi cells endogenously express three of the four ErbB-receptors.  Their 
ErbB-receptor’s ability to heterodimerize with each other and activate by binding to 
nine different ligands, creates an overlapping spider web of activation, deactivation, 
downregulation and recycling.  This network of differential signaling limits how many 
comparisons you can perform at one time and requires careful experimental design 
to limit confusion and focus analysis.  Direct comparison between a limited number 
of receptors and ligands that only bind one receptor is the best way is to compare 
ligands.  However, pharmacological inhibition can have off target effects and 
knockdown can lead to compensatory production or increased activity of relative 
proteins.  Choosing cell lines that endogenously express a physiologically relevant 
number of receptors would be ideal, as that would ensure studying a biological 
process.  However, not every cell line has known receptors or receptor densities, and 
analysis to deduced receptor concentrations in a variety of cells would be 
insurmountable. 
 Another limitation to this study is the lack of quality human specific antibodies 
to analyze phosphorylation levels of many of the effectors associated with 
proliferation and migration in the EGFR signaling pathway.  PI3K is a critical regulator 
of the migration pathway, but human specific antibodies for phosphorylated PI3K 
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proteins are currently not available.  Often, a 32P-ATP assay is used to assess PI3K 
activity following ligand activation, but this is a multi-step process that requires the 
right equipment and expertise to analyze the assay effectively. 
Strengths of This Work 
 A major strength of this work is the study focuses on the basic biology related 
to a physiologically important process, cell migration.  The basic mechanism assay 
(receptor phosphorylation/PLA) results reveal molecular interactions that are 
quantifiable and translatable to other cells lines besides cornea epithelial cells.    
 The in vitro cultivation of cell lines derived from the corneal epithelium has 
become a powerful technique for research.  It is also important to note that using a 
substitute animal model used to assay drugs and other compounds is ethically 
responsible.  While it is still required to test new drugs and compounds in vivo, 
performing research in an in vitro model can decrease the number and duration of 
animals used in a study.           
Future Directions 
 The study of EGFR activation, regulation and signaling continues to be 
important for wound healing, cancer screening, regulation of cancer drug side effects 
and EGFR targeted therapies.  Even though a thorough understanding of individual 
receptor mechanics is available, the impact of ligands and dimer pairings is still 
unclear.  Can a ligand be clinically useful to improve the quality of wound healing 
while also decreasing the time to heal?  A comprehensive study looking at ligand 
binding, receptor dimers and effectors collectively would clarify the contributions of 
each of the EGF-like ligands.  Looking at receptors systematically in cell lines that 
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endogenously contain certain ErbB rectors can eliminate some of the complexities 
without interrupting the normal cell function.  A large-scale study of ErbB receptors 
in a variety of cells from multiple tissue types, normal and cancerous, would afford 
researchers the opportunity to choose cell lines with specific receptor qualities and 
document physiology changes after ligand activation.   Multiplex assays have become 
more mainstream, but the expense of the equipment and the price of consumables 
associated with the assay have limited the scope of its contribution to ErbB receptor 
signaling.  Multi-plex assays that could analyze the phosphorylation of every known 
effector would allow for direct comparison between ligand effects on the signaling 
pathways.  Being able to analyze at multiple time points would be cumbersome, but 
necessary as effectors are activated at different times during endocytosis. 
A much deeper understanding the effectors involved in BTC induced cell 
migration can not only be helpful to produce new treatments for corneal wounds, but 
also be relative to cancer therapies that target EGFR, EGFR signaling and manipulate 
receptor agonist/antagonist.  BTC overexpression has been associated with certain 
cancer types, and using the data acquired from this study, you can see the possible 
contribution of BTC in EGFR inhibitor resistance.   
The individual contributions of all of the ErbB-receptor ligands, and how 
dimer-pairing choice initiates downstream effectors, is critical to formulating new 
treatments for corneal wound healing.  Just as important as quality of life 
improvements with rapid wound repair, is answering the question of how 
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